Quintet Private Bank Europe S.A. Raises Stock Position in Eli Lilly and Company $LLY

Key Points

• Quintet Private Bank Europe increased its Eli Lilly position by 55.8% in the third quarter, bringing its holdings to 44,028 shares valued at approximately $50.9 million. Institutional investors collectively own 82.53% of the company.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $1,313.43, despite insider sales totaling $15.96 million over the past 90 days.
• Eli Lilly shares recently fell 2.9% to $1,154.72, while the company reported quarterly earnings and revenue above expectations, with revenue rising 47.7% year over year.

Quintet Private Bank Europe S.A. boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 55.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 44,028 shares of the company's stock after purchasing an additional 15,762 shares during the quarter. Eli Lilly and Company comprises about 2.4% of Quintet Private Bank Europe S.A.'s holdings, making the stock its 10th biggest position. Quintet Private Bank Europe S.A.'s holdings in Eli Lilly and Company were worth $50,944,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new stake in Eli Lilly and Company in the 4th quarter valued at about $30,000. Maseco LLP increased its position in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after acquiring an additional 28 shares during the last quarter. Aventus Investment Advisors Inc. increased its position in shares of Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company's stock valued at $34,000 after purchasing an additional 27 shares during the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. raised its stake in shares of Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock worth $37,000 after purchasing an additional 15 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on LLY. HSBC boosted their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a research note on Thursday, September 10th. Bank of America upped their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a research report on Friday, July 10th. The Goldman Sachs Group raised their target price on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a "buy" rating in a research note on Thursday, September 17th. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a report on Friday, September 18th. Finally, Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,313.43.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company's stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst raises price target: Cantor Fitzgerald lifted its LLY price target to $1,440 from $1,410 and maintained an “overweight” rating, signaling confidence in Lilly’s long-term earnings outlook. Benzinga coverage
• Positive Sentiment: Technical momentum improves: LLY recently moved above its 50-day moving average, a technical signal that may attract short-term buyers and suggests improving near-term momentum. Eli Lilly overtakes 50-day moving average
• Positive Sentiment: Pipeline supports the long-term case: Investors continue to highlight strong GLP-1 demand, oncology growth and next-generation obesity candidate retatrutide. Retatrutide’s potential efficacy and a possible FDA filing in 2027 could provide another major growth catalyst. Three bargains outside AI
• Neutral Sentiment: Oncology remains a developing growth driver: Jaypirca, Inluriyo and Retevmo could help offset slower Verzenio sales and declines from mature products, although the financial impact will depend on commercial execution and upcoming results. Eli Lilly oncology portfolio ahead of earnings
• Negative Sentiment: Valuation and competition remain overhangs: Analysts note that LLY trades at a demanding multiple, while increasing competition in the GLP-1 market and potential pricing pressure could limit the pace of future earnings growth. New WHO childhood-obesity guidance may also create uncertainty around the market’s long-term expansion. Is the LLY dip a buying opportunity?

Eli Lilly and Company Stock Down 2.9%

Eli Lilly and Company stock traded down $34.00 during mid-day trading on Thursday, reaching $1,154.72. The stock had a trading volume of 1,479,126 shares, compared to its average volume of 2,966,079. The company has a 50-day moving average price of $1,173.51 and a two-hundred day moving average price of $1,094.59. Eli Lilly and Company has a one year low of $783.85 and a one year high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market capitalization of $1.09 trillion, a price-to-earnings ratio of 38.71, a PEG ratio of 1.42 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the firm earned $6.31 earnings per share. The firm's quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts expect that Eli Lilly and Company will post 36.66 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.